

ALERTA Nº 12/2019

PROGRAMME	HORIZON 2020 (2014-2020)
CALL	EIC Pathfinder pilot. (FET-Proactive) Boosting emerging technologies. FETPROACT EIC-05-2019-
FUNDING BODY	<ul style="list-style-type: none"> • European Commission
CALL FOCUS	<ul style="list-style-type: none"> • FET Proactive aims to identify the future and emerging technological paradigms with highest potential for Europe's economy and society. For each of them, it looks to establish a broad and solid European basis in terms of knowledge, key technological building blocks and interdisciplinary communities. By reaching out well beyond the research world, it ensures that Europe has the best 'first mover' position to capitalise rapidly and effectively on emerging societal and industrial opportunities. • <u>Specific Challenge</u>: To explore and consolidate a new technological direction in order to put it firmly on the map as a viable paradigm for future technology. To foster the interdisciplinary communities that are able to drive this forward, extending from the participating consortia to a wider European pool of expertise. To stimulate the emergence of a European innovation ecosystem around a new technological paradigm, well beyond the world of research alone. • <u>Scope</u>: proposals are sought for cutting-edge high-risk / high-reward research and innovation projects that aim to demonstrate a new technological paradigm within the scope of one of the following sub-topics: <ul style="list-style-type: none"> a. Human-Centric AI. Artificial intelligence (AI) is gaining more and more footholds in various aspects of our life. However, machine learning algorithms are difficult to understand, opaque and may have implicit biases in their decision making. Explicability has become an essential element if users are to trust, accept and adopt the next generation of intelligent machines on a wider scale. This initiative seeks to advance to the next AI frontier with verifiable, evidence-based features of trustworthiness (i.e., reliable and unbiased alignment of values, goals and beliefs) and transparency (explainable performance), exploring radically new approaches (e.g., inspired from neuroscience, cognition or social science). For instance, explanation could be more tightly intertwined with the decision making process itself so that decisions can be challenged, interpreted, refined and adjusted through mutual exchange, introspection (e.g., self-awareness of biases, reflecting on the internal functioning of the learning system, or on what caused a wrong or unacceptable decision) and active learning of both system and user, for example through dialogue or other forms of multi-modal interaction aimed at establishing mutual trust. New data collection and ownership/governance models that go beyond the dominant off-line and centralised data processing should be investigated, and new avenues, such as for incremental,
PRIORITY SUB-TOPICS AND TYPE OF ACTION	

PROGRAMME	HORIZON 2020 (2014-2020)
	<p>unsupervised, active, one-shot and ‘small data’ machine learning, should be explored. The projects are expected to contribute to the wider debate on the sociotechnical, organisational and AI-ethical dimensions of such technologies and systems, and link to the ‘Commission’s broader AI strategy.</p> <p>b. Implantable autonomous devices and materials. Radically new biomedical technologies that will lead to enhanced life quality for people are urgently needed, particularly for mitigating the impact of chronic health conditions that are placing a rapidly growing and ultimately unsustainable burden on healthcare systems. A key goal will be to demonstrate dramatically extended functional lifetimes of implantable devices, for example, through incorporation of smart sensing, self-awareness, adaptation (form and/or function) and self-repair capabilities. Included are mobile micro/nano devices based on biological models that can perform advanced functions e.g. site specific automigration, ability to distinguish tissue types (diseased, normal) and perform highly localised actions (e.g., delivery of therapeutic agents). Entities incorporating (bio)materials that provide instances of totally autonomous biomimetic behaviour and in-situ integration and adaptation are particularly welcome, such as an ability to blend-in with the native biological environment, to independently generate power, synthesise active agents or sense and respond to changes in the local molecular environment. Work on ethical implications should be included.</p> <ul style="list-style-type: none"> • <u>Expected Impact:</u> <ul style="list-style-type: none"> ✓ Scientific and technological contributions to the foundation and consolidation of a radically new future technology. ✓ Potential for future returns in terms of societal or economic innovation or market creation. ✓ Spreading excellence and building leading innovation capacity across Europe by involvement of key actors that can make a difference in the future, for example excellent young, researchers, ambitious high-tech SMEs or first-time participants to FET under Horizon 202018. ✓ Build-up of a goal oriented interdisciplinary community (within and beyond the consortium). ✓ Emergence of an innovation ecosystem around a future technology in the theme addressed from outreach to and partnership with high potential actors in research and innovation, and from wider stakeholder/public engagement, with due consideration of aspects such as education, gender differences and long-term societal, ethical and legal implications. • <u>Type of action:</u> Research and Innovation action

PROGRAMME	HORIZON 2020 (2014-2020)
INSTRUMENT FUNDING LEVEL	<ul style="list-style-type: none"> • Research & Innovation Actions: Maximum of 100% of the total eligible costs
ELIGIBLE COSTS	<ul style="list-style-type: none"> • Personnel cost • Other direct cost: travel and subsistence; equipment, Informatics, consumables, among other needed cost. • Subcontracting • Indirect cost (25% total direct cost, except subcontracting)
REMARKS	<ul style="list-style-type: none"> • Minimum consortium Research & innovation action: At least 3 legal entities established in a different Member State or associated country. All 3 legal entities shall be independent of each other. • Information on the outcome of the evaluation: Maximum 5 months from the final date for submission. Indicative date for the signing of grant agreements: Maximum 8 months from the final date for submission • <i>Members of consortium are required to conclude a consortium agreement, in principle prior to the signature of the grant agreement.</i>
INDICATIVE BUDGET	<ul style="list-style-type: none"> • 52.00 (EUR million)
DEADLINE	<ul style="list-style-type: none"> • 03/09/2019
MORE INFORMATION	Participant Portal
DISTRIBUCIÓN	<ul style="list-style-type: none"> • Socios numerarios de la Asociación IBV y socios corporativos de la Asociación CVIDA • Actualizado 23/04/2019



El Instituto de Biomecánica (IBV) pone a disposición de los socios un servicio de alertas de ayudas y subvenciones públicas de apoyo a la I+D.

El objetivo de este servicio es informar a las empresas, a través del envío de fichas-resumen, de las ayudas y subvenciones convocadas por la Administración Autonómica Valenciana, por la Administración Central y por la Unión Europea, con la intención de identificar posibles vías de financiación de sus proyectos empresariales.

Estas fichas contienen información sobre destinatarios, condiciones y plazos para concurrir a las convocatorias y son enviadas a las socios, de forma temprana, una vez salen publicadas en los boletines oficiales correspondientes.